News

Pharmaceutical Commerce1h
BioNTech, BMS to Co-Design and Co-Commercialize New Antibody Candidate for Various Types of Tumors
Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ...
BioNTech's Deal With Bristol Myers Over BNT-327 May Be Overhyped
BioNTech SE's $11.1B oncology move signals potential, but clinical hurdles remain. Click for my look at the BNTX deal with ...